Current Report Filing (8-k)
14 January 2021 - 12:06AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 13, 2021 (January 13, 2021)
LUCKWEL
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
333-187874
|
|
46-1660653
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
125
Cambridge Park Drive, Suite 301,Cambridge
|
|
MA
02140
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, include area code +1 (617) 430 5222
245
First Street, Suite 1800, Cambridge, MA 02142
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
1.01 Entry into a Material Definitive Agreement
On
January 5, 2021, Luckwel Pharmaceuticals, Inc. (“ we” or the “Company”) entered into a subscription agreement
with Xue Hua Peng for the purchase and sale of an aggregate of 300,000 shares of common stock of the Company, par value $0.01
(the “Shares”), at a price of US$0.40 per Share for total gross proceeds of US$120,000 (the “Offering”).
The proceeds from the Offering will be used for general corporate purposes, including infrastructure, product development, marketing
and sales and working capital. Details of the sales of the Shares are provided in Item 3.02 of this Current Report on Form 8-K
and incorporated herein by reference.
The
foregoing description of the subscription agreement does not purport to be complete and is qualified in its entirety by reference
to the full text of the form of subscription agreement entered into between the Company and Ms. Peng under the subscription agreement
which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated herein by reference.
Item
3.02 Unregistered Sales of Equity Securities
On
January 12, 2021, we completed a private placement offering of 300,000 Shares at a price of US$0.40 per Share for total proceeds
of US$120,000 to Xue Hua Peng with the Offering that had not been registered under the United States Securities Act of 1933, as
amended (the “Securities Act”) and that had not been reported on our previously filed periodic reports filed under
the United States Securities Exchange Act of 1934, as amended (the “Exchange Act”) pursuant to Rule 903 of Regulation
S of the Securities Act.
We
completed this Offering of the Shares and pursuant to Rule 903 of Regulation S of the Securities Act on the basis that the sale
of the Shares was completed in “offshore transactions”, as defined in Rule 902(h) of Regulation S. We did not engage
in any “directed selling efforts”, as defined in Regulation S, in the United States in connection with the sale of
the Shares. The investor represented to us that she was not a U.S. person, as defined in Regulation S, and was not acquiring the
Shares for the account or benefit of a U.S. person.
She
also represented that she was acquiring the Shares for investment only and not with a view towards, or for resale in connection
with, the public sale or distribution thereof. The subscription agreement executed between us and her included statements that
the Shares had not been registered pursuant to the Securities Act and that the Shares may not be offered or sold in the United
States unless the Shares are registered under the Securities Act or pursuant to an exemption from the Securities Act. She agreed
by execution of the subscription agreement: (i) to resell the Shares purchased/obtained only in accordance with the provisions
of Regulation S, pursuant to registration under the Securities Act or pursuant to an exemption from registration under the Securities
Act; (ii) that we are required to refuse to register any sale of the Shares purchased/obtained unless the transfer is in accordance
with the provisions of Regulation S, pursuant to registration under the Securities Act or pursuant to an exemption from registration
under the Securities Act; and (iii) not to engage in hedging transactions with regards to the Shares purchased/obtained unless
in compliance with the Securities Act. All Shares issued were endorsed with a restrictive legend confirming that the Shares had
been issued pursuant to Regulation S of the Securities Act and could not be resold without registration under the Securities Act
or an applicable exemption from the registration requirements of the Securities Act.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
LUCKWEL
PHARMACEUTICALS INC.
|
|
|
Date:
January 13, 2021
|
|
/s/
Kingrich Lee
|
|
Name:
|
Kingrich
Lee
|
|
Title:
|
Chief
Executive Officer and Chief Financial Officer
|
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
Historical Stock Chart
From May 2024 to Jun 2024
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Luckwel Pharmaceuticals Inc (GM) (OTCMarkets): 0 recent articles
More Luckwel Pharmaceuticals Inc. News Articles